Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion--CAtholic Total Occlusion Study (CATOS) trial.

摘要: Background: Limited data are available regarding the direct comparison of angiographic and clinical outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) for chronic total occlusion (CTO). Methods Results: A prospective, randomized, multicenter trial was conducted to evaluate non-inferiority a zotarolimus-eluting stent (ZES; Endeavor Sprint®, n=80) sirolimus-eluting (SES; Cypher®, in patients CTO lesion reference vessel diameter ≥2.5mm. The primary endpoint in-segment binary restenosis rate at 9-month follow-up. Key secondary endpoints included target failure (TVF; including cardiac death, myocardial infarction, revascularization) Academic Research Consortium-defined definite/probable thrombosis (ST) within 12 months. ZES non-inferior SES respect endpoint, which occurred 14.1% (95% confidence interval [CI]: 6.0-22.2) 13.7% (95%CI: 5.8-21.6) patients, respectively (non-inferiority margin, 15.0%; P <0.001). There were no significant between-group differences TVF (10.0% vs. 17.5%; P=0.168) nor ST (0.0% 1.3%; P=0.316) during 12-month Conclusions: effectiveness safety similar those therefore it is good treatment option undergoing PCI DESs. (Circ J 2012; 76: 868-875)